Sample size.
There was no formal sample size calculation for this study. However, the number of participants planned to receive COVID-HIGIV was deemed sufficient to descriptively assess safety and PK of three COVID-HIGIV dose levels of healthy adults. In total, 28 participants were planned for the study: eight participants for each of the three COVID-HIGIV dose levels, and four participants for the placebo arm.